NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Gains FDA Nod for Preservative-Free Ketamine Suitability Petition

• FDA grants NRx Pharmaceuticals approval of a Suitability Petition for single-patient preservative-free ketamine.
• The decision enables re-filing of an Abbreviated New Drug Application (“ANDA”) for the company’s KETAFREE(TM) product, which the company has now done.
• Current ketamine formulations use multidose vials with a toxic preservative, Benzethonium Chloride.
• U.S. ketamine market is estimated at $750 million annually, presenting a significant commercial opportunity.
• NRx is also advancing NRX-100 and NRX-101 for suicidal depression and PTSD, both with FDA designations.
• The move aligns with U.S. policy goals on reshoring drug production and reducing toxic additives.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced it has received approval from the U.S. Food and Drug Administration (“FDA”) for its Suitability Petition to advance KETAFREE(TM), a preservative-free version of ketamine (https://ibn.fm/qFzsh). The ruling allows the company to re-file its Abbreviated New Drug Application (“ANDA”) for the product, which it has now done, a key step in bringing it to market (https://ibn.fm/nogJi).

Currently, ketamine is sold in multidose vials that require preservatives to maintain sterility after repeated use. The most common additive, Benzethonium Chloride, is known to be toxic. NRx’s proposed alternative eliminates preservatives by using single-patient dosing, a change the company argues improves safety and aligns with updated public health priorities.

The FDA’s decision comes at a time when the administration has emphasized two objectives: reshoring essential pharmaceutical production to the United States and reducing toxic preservatives in food and medicine. Both priorities were highlighted in recent statements by FDA and HHS leadership, giving added policy momentum to initiatives like NRx’s KETAFREE(TM).

The size of the opportunity is notable. The U.S. ketamine market is currently estimated at $750 million annually. While ketamine has established medical uses, particularly as an anesthetic, demand has grown due to off-label applications in mental health care. NRx believes its preservative-free product can capture market share on safety grounds alone, while serving as a foundation for further clinical programs.

“Last week, NRx was honored to be selected to attend a ‘listening session’ hosted by the FDA Commissioner, for biotechnology CEOs. We appreciate FDA’s rapid response on the requested Suitability Petition and look forward to bringing our preservative-free presentation of ketamine to the US market at the earliest possible moment,” said Jonathan C. Javitt, MD, MPH, Chairman and CEO of NRx Pharmaceuticals.

Beyond KETAFREE(TM), NRx continues to build out a pipeline of therapies focused on central nervous system disorders. Its preservative-free intravenous formulation NRX-100 has received Fast Track Designation for the treatment of suicidal depression, including bipolar depression. A related program, NRX-101, has earned Breakthrough Therapy Designation for suicidal bipolar depression. These programs complement the KETAFREE(TM) initiative, underscoring the company’s emphasis on addressing urgent psychiatric needs.

Ketamine remains a focus of increasing clinical and public interest. Beyond anesthesia, its rapid-acting antidepressant effects have drawn attention for use in treatment-resistant depression and PTSD. However, the lack of FDA-approved, safe, standardized formulations has limited broader adoption. If successful, NRx’s KETAFREE(TM) could fill an important gap in both safety and accessibility. As the U.S. continues to push for domestic drug production and higher standards of safety in pharmaceutical manufacturing, NRx’s initiative could benefit from regulatory alignment and potential support programs.

For more information, visit the company’s website at www.NRxPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

About PsychedelicNewsWire

PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com

PsychedelicNewsWire is powered by IBN